NTRK1 and medullary thyroid gland carcinoma: In a phase 3 trial in MTC patients, vandetanib, a VEGFR2/RET inhibitor, showed clinical benefits that were independent of RET gene mutation status [34], suggesting that multiple receptor tyrosine kinase inhibitors may be able to show antitumor activity based on antiangiogenesis activity targeting VEGFR2.